Bloom Energy Shorts Cover as Analyst Targets Scatter After Earnings Rout

Bloom Energy emerges from one of the most disorienting fortnights in its recent history: two earnings-day drops totalling nearly 30 percentage points, a 30% monthly loss, yet a 5% weekly gain and a street consensus that still sits well above the current price.

The most striking feature of positioning right now is the gap between where analysts think the stock belongs and where it is trading. The mean analyst price target is $284.88, against a Friday close of $203.17. That is a 40% implied return, yet the targets themselves are far from coherent. Morgan Stanley raised its Overweight target to $335 on October 23. RBC held its Outperform at $335 the same day. JP Morgan, also maintaining Overweight, cut from $314 to $292. At the other end, Wells Fargo kept an Equal-Weight with a $182 target, below the current price. Barclays raised its Equal-Weight target to $316. Citigroup, on October 29, nudged its Neutral target to $284. The pattern is one where bulls are lifting numbers after better-than-expected results, while cautious-rated analysts are scattered across a $100-plus range. The bull case rests on a backlog that could exceed $20 billion, FY26 guidance raised to $4.4 to $4.6 billion in revenue, and a cash position of roughly $2.5 billion with minimal debt. Bears point to customer concentration, execution risk around penalty clauses, and a valuation that the bear case describes as roughly 40 times 2027 EBITDA, leaving little buffer for operational misses.

Short positioning has actually been easing through the drawdown, which is the counterintuitive signal worth watching. Short interest has fallen from a September peak near 27 million shares to 19.5 million, now 8.2% of the free float and down more than 22% over the past month. The week-on-week change is a modest 2.4% decline. Borrow availability is loose at 659% of outstanding short interest, meaning there are roughly six and a half shares available to borrow for every one already lent out. That compares with the 52-week tightest reading of 476%, reached in late September. The cost to borrow is 0.40%, up around 11% on the week but still firmly in the low category and well within normal ranges. There is no squeeze pressure in the lending market. Options carry a put/call ratio of 1.11, just below its 20-day mean of 1.14 and about one standard deviation beneath that average: options positioning is, if anything, marginally less defensive than usual, not more. The lending and options data together do not support a picture of shorts pressing aggressively into the weakness.

Ownership flows add texture to the picture. BlackRock filed a Schedule 13G/A on October 27, disclosing a stake raised to 7.5% from 6.0%. Vanguard Capital Management filed a fresh Schedule 13G on October 30, disclosing 7.39% of the class. JP Morgan Asset Management added roughly 4.7 million shares in the quarter to September 30, bringing its position to 1.82% of shares. These are passive and quasi-passive inflows, not activist intent. The one activist on the register is SK ecoplant, a South Korean infrastructure company that filed a Schedule 13D and most recently disclosed a 4.7% stake in August 2025. As the disclosure caveat applies here: the SK ecoplant position is as last filed, and a holder below 5% may not file again. The net insider picture over the past 90 days is a sale of roughly 90,000 shares worth around $21.8 million, driven primarily by the Chief Commercial Officer selling under pre-arranged 10b5-1 plans and the Chief Accounting Officer selling in September. Planned sales carry less informational weight than discretionary transactions, but the absence of open-market buying from senior management is a visible gap given the scale of the price decline.

Retail attention has spiked. The ORTEX Wikipedia views signal shows a z-score of 2.37 as of October 22, reflecting a significant jump in English Wikipedia article views and distinct ORTEX page viewers relative to the prior 90 days. This is an attention metric, not a revenue or fundamental indicator, but it does confirm that Bloom has drawn in a new audience during the drawdown. The next scheduled earnings event is February 4, 2027, giving the stock 96 days before the next major fundamental test. Valuation multiples have compressed with the price: the price/earnings multiple has fallen roughly 18 points over the past 30 days to around 44.8 times, and EV/EBITDA has dropped about 6.5 turns to 37.4 times. EPS momentum factor scores rank in the 94th percentile on a 30-day basis and the 92nd on 90 days, which means estimate revisions have been running strongly upward even as the share price fell. That tension between rising estimates and a falling price is one of the cleaner signals in the current setup.

What to watch next is whether the gap between the consensus target and the current price closes through price recovery or through further target cuts as analysts absorb the full implications of the two-session earnings selloff, and whether insider activity shifts from planned sales under 10b5-1 programmes toward any discretionary buying at these levels.